Cost-effectiveness analysis of dupilumab versus omalizumab, mepolizumab and benralizumab added to the standard of care in adults with severe asthma in Colombia

CONCLUSIONS: Dupilumab 200 mg was strongly dominant versus omalizumab 450 mg and600 mg, mepolizumab 100 mg and benralizumab 30 mg; however,cost-effectiveness was not demonstrated versus omalizumab 300 mg.These findings might aid in the selection of a biologic to treatsevere type 2 asthma.PMID:37994432 | DOI:10.1080/14737167.2023.2282668
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Authors: Source Type: research